// App-Quantinova.ai

SA-OR19 : Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6

Researchers

Presenter

  • Tuttle KatherineR

Principal Investigators

  • Cherney David

  • Hadjadj Samy

  • Idorn Thomas

  • Mosenzon Ofri

  • Perkovic Vlado

  • Rasmussen Soren

  • Wolthers Benjamin

  • Bain StephenC

Medical Centers

  • Institute of Translational Health Sciences Kidney Research Institute and Nephrology Division University of Washington Seattle Washington United States

  • Division of Nephrology University Health Network University of Toronto Toronto Ontario Canada

  • L'institut du thorax INSERM CNRS University of Nantes CHU Nantes Nantes France

  • Novo NordiskA/S, Soborg, Denmark

  • Diabetes Unit Department of Endocrinology and Metabolism Hadassah Medical Center Hebrew University of Jerusalem Jerusalem Israel

  • University of New South Wales Sydney New South Wales Australia

  • Diabetes Research Unit Swansea University Medical School Swansea United Kingdom

Locations

  • United States

  • Canada

  • France

  • Denmark

  • Israel

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Semaglutide

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved